These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 28109665)

  • 21. Adjunctive divalproex and hostility among patients with schizophrenia receiving olanzapine or risperidone.
    Citrome L; Casey DE; Daniel DG; Wozniak P; Kochan LD; Tracy KA
    Psychiatr Serv; 2004 Mar; 55(3):290-4. PubMed ID: 15001730
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A randomized, flexible-dose, quasi-naturalistic comparison of quetiapine, risperidone, and olanzapine in the short-term treatment of schizophrenia: the QUERISOLA trial.
    Sacchetti E; Valsecchi P; Parrinello G;
    Schizophr Res; 2008 Jan; 98(1-3):55-65. PubMed ID: 17933497
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A randomized, double-blind comparison of risperidone versus low-dose risperidone plus low-dose haloperidol in treating schizophrenia.
    Lin CH; Kuo CC; Chou LS; Chen YH; Chen CC; Huang KH; Lane HY
    J Clin Psychopharmacol; 2010 Oct; 30(5):518-25. PubMed ID: 20814315
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A randomized double-blind study of risperidone and olanzapine in the treatment of schizophrenia or schizoaffective disorder.
    Conley RR; Mahmoud R
    Am J Psychiatry; 2001 May; 158(5):765-74. PubMed ID: 11329400
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Olanzapine versus clozapine in treatment-resistant or treatment-intolerant schizophrenia.
    Bitter I; Dossenbach MR; Brook S; Feldman PD; Metcalfe S; Gagiano CA; Füredi J; Bartko G; Janka Z; Banki CM; Kovacs G; Breier A;
    Prog Neuropsychopharmacol Biol Psychiatry; 2004 Jan; 28(1):173-80. PubMed ID: 14687871
    [TBL] [Abstract][Full Text] [Related]  

  • 26. D-serine efficacy as add-on pharmacotherapy to risperidone and olanzapine for treatment-refractory schizophrenia.
    Heresco-Levy U; Javitt DC; Ebstein R; Vass A; Lichtenberg P; Bar G; Catinari S; Ermilov M
    Biol Psychiatry; 2005 Mar; 57(6):577-85. PubMed ID: 15780844
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Safety and efficacy of olanzapine monotherapy and olanzapine with a mood stabilizer in 18-week treatment of manic/mixed episodes for Japanese patients with bipolar I disorder.
    Katagiri H; Takita Y; Tohen M; Higuchi T; Kanba S; Takahashi M
    Curr Med Res Opin; 2012 May; 28(5):701-13. PubMed ID: 22356118
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Standard olanzapine versus placebo and ineffective-dose olanzapine in the maintenance treatment of schizophrenia.
    Dellva MA; Tran P; Tollefson GD; Wentley AL; Beasley CM
    Psychiatr Serv; 1997 Dec; 48(12):1571-7. PubMed ID: 9406266
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Aripiprazole versus olanzapine in the treatment of schizophrenia: a clinical study from India.
    Jindal KC; Singh GP; Munjal V
    Int J Psychiatry Clin Pract; 2013 Feb; 17(1):21-9. PubMed ID: 22339214
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Olanzapine vs haloperidol in geriatric schizophrenia: analysis of data from a double-blind controlled trial.
    Kennedy JS; Jeste D; Kaiser CJ; Golshan S; Maguire GA; Tollefson G; Sanger T; Bymaster FP; Kinon BJ; Dossenbach M; Gilmore JA; Breier A
    Int J Geriatr Psychiatry; 2003 Nov; 18(11):1013-20. PubMed ID: 14618553
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A double-blind, randomized comparative study of aripiprazole and olanzapine in patients with schizophrenia.
    Fleischhacker WW; McQuade RD; Marcus RN; Archibald D; Swanink R; Carson WH
    Biol Psychiatry; 2009 Mar; 65(6):510-7. PubMed ID: 18986646
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A multicenter, inpatient, phase 2, double-blind, placebo-controlled dose-ranging study of LY2140023 monohydrate in patients with DSM-IV schizophrenia.
    Kinon BJ; Zhang L; Millen BA; Osuntokun OO; Williams JE; Kollack-Walker S; Jackson K; Kryzhanovskaya L; Jarkova N;
    J Clin Psychopharmacol; 2011 Jun; 31(3):349-55. PubMed ID: 21508856
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A double-blind, randomized comparison study of efficacy and safety of intramuscular olanzapine and intramuscular haloperidol in patients with schizophrenia and acute agitated behavior.
    Chan HY; Ree SC; Su LW; Chen JJ; Chou SY; Chen CK; Chen YS
    J Clin Psychopharmacol; 2014 Jun; 34(3):355-8. PubMed ID: 24743717
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Olanzapine long-acting injection: a 24-week, randomized, double-blind trial of maintenance treatment in patients with schizophrenia.
    Kane JM; Detke HC; Naber D; Sethuraman G; Lin DY; Bergstrom RF; McDonnell D
    Am J Psychiatry; 2010 Feb; 167(2):181-9. PubMed ID: 20008947
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Antipsychotic medication in adolescents suffering from schizophrenia: a meta-analysis of randomized controlled trials.
    Ardizzone I; Nardecchia F; Marconi A; Carratelli TI; Ferrara M
    Psychopharmacol Bull; 2010; 43(2):45-66. PubMed ID: 21052042
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The efficacy and safety of 12 weeks of treatment with sertindole or olanzapine in patients with chronic schizophrenia who did not respond successfully to their previous treatments: a randomized, double-blind, parallel-group, flexible-dose study.
    Kwon JS; Mittoux A; Hwang JY; Ong A; Cai ZJ; Su TP
    Int Clin Psychopharmacol; 2012 Nov; 27(6):326-35. PubMed ID: 22850268
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Efficacy and tolerability of olanzapine, quetiapine, and risperidone in the treatment of early psychosis: a randomized, double-blind 52-week comparison.
    McEvoy JP; Lieberman JA; Perkins DO; Hamer RM; Gu H; Lazarus A; Sweitzer D; Olexy C; Weiden P; Strakowski SD
    Am J Psychiatry; 2007 Jul; 164(7):1050-60. PubMed ID: 17606657
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Childhood-onset schizophrenia: A double-blind, randomized clozapine-olanzapine comparison.
    Shaw P; Sporn A; Gogtay N; Overman GP; Greenstein D; Gochman P; Tossell JW; Lenane M; Rapoport JL
    Arch Gen Psychiatry; 2006 Jul; 63(7):721-30. PubMed ID: 16818861
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Antipsychotic switching versus augmentation among early non-responders to risperidone or olanzapine in acute-phase schizophrenia.
    Hatta K; Otachi T; Fujita K; Morikawa F; Ito S; Tomiyama H; Abe T; Sudo Y; Takebayashi H; Yamashita T; Katayama S; Nakase R; Shirai Y; Usui C; Nakamura H; Ito H; Hirata T; Sawa Y;
    Schizophr Res; 2014 Sep; 158(1-3):213-22. PubMed ID: 25086659
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A 6-week randomized, double-blind, placebo-controlled, comparator referenced trial of vabicaserin in acute schizophrenia.
    Shen JH; Zhao Y; Rosenzweig-Lipson S; Popp D; Williams JB; Giller E; Detke MJ; Kane JM
    J Psychiatr Res; 2014 Jun; 53():14-22. PubMed ID: 24613032
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.